What is Oric Pharmaceuticals, Inc.'s market cap?

Oric Pharmaceuticals, Inc. (ORIC) has a market capitalization of $1.2B and trades on NASDAQ.

Who are Oric Pharmaceuticals, Inc.'s competitors?

Oric Pharmaceuticals, Inc.'s key competitors include Pfizer, Cullinan Therapeutics, ArriVent BioPharma, and others. These companies compete in similar markets and product categories.

Who does Oric Pharmaceuticals, Inc. partner with?

Oric Pharmaceuticals, Inc.'s notable partners include Johnson & Johnson, Bayer, Voronoi Inc., and others.

Where is Oric Pharmaceuticals, Inc. headquartered?

Oric Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 102 people. It has been publicly traded since 2020.

Oric Pharmaceuticals, Inc.

ORIC

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance mechanisms in cancer.

Market cap

$1.24B+36.3%

Net income-$135.2M-1.8%

Free cash flow-$111.2M+4.4%

EPS (diluted)-$1.41+24.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

EPS-$0.34Miss by $0.03

Read the full report

Next report

Aug 11, 2026 (In 1 week)

EPS estimate-$0.36

Financials

Q1 2026

Income statement

See full

Operating income-$39.6M-21.1%

Net income-$35.8M-19.1%

EPS (diluted)-$0.34+19.0%

Balance sheet

See full

Cash & equivalents$56.4M+14.3%

Total debt$3.3M+2.6%

Total equity$415.6M+89.1%

Total assets$436.8M+79.8%

Cash flow

See full

Operating cash flow-$32.4M+0.3%

CapEx$2.0K-99.5%

Free cash flow-$32.4M+1.5%

Valuation & ratios

Valuation

See full

Market cap$1.24B+36.3%

Enterprise value$1.19B+35.3%

Returns & leverage

See full

Return on equity-42.6%-4.6pp

Debt / equity0×0.0×

Current ratio16.3×+4.3×

Competitors

By market cap

Pfizer$140.61B+1.7%

CG Oncology$6.5B+229%

ArriVent BioPharma, Inc.$1.4B+82.9%

Oric Pharmaceuticals, Inc.$1.2B+30.6%

Olema Pharmaceuticals, Inc.$1.0B+217%

ALX Oncology Holdings Inc.$271.8M+712%

Black Diamond Therapeutics, Inc.$99.1M-40.5%

Oncolytics Biotech, Inc.$95.5M-9.3%

By revenue growth

CG Oncology+666%

Pfizer+1.4%

By net margin

Pfizer15.65%+6.3pp

CG Oncology-3,682.61%+12,263pp

Profile

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance mechanisms in cancer. The company leverages expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to advance a pipeline of small molecule inhibitors. Its core value proposition lies in identifying and targeting innate, acquired, and bypass resistance pathways to improve the efficacy and duration of oncology treatments.

Competitive position

ORIC is a clinical-stage developer specializing in cancer resistance, utilizing a precision medicine approach with a management team experienced in successful oncology drug commercialization.

GeographiesUnited States, South Korea

Customer segmentsPatients, Healthcare Providers, Pharmaceutical Companies

Business modelR&D, IP Licensing

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic Institutions, IP Licensors

CustomersHospitals, Specialty Pharmacies, Biopharmaceutical Partners

CountryUnited States of America

Listed2020

Employees102.0

CEOJacob Chacko

SectorHealthcare

IndustryBiotechnology

Websiteoricpharma.com

FilingsSEC EDGAR

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s market cap?: Oric Pharmaceuticals, Inc. (ORIC) has a market capitalization of $1.2B and trades on NASDAQ.
Who are Oric Pharmaceuticals, Inc.'s competitors?: Oric Pharmaceuticals, Inc.'s key competitors include Pfizer, Cullinan Therapeutics, ArriVent BioPharma, and others. These companies compete in similar markets and product categories.
Who does Oric Pharmaceuticals, Inc. partner with?: Oric Pharmaceuticals, Inc.'s notable partners include Johnson & Johnson, Bayer, Voronoi Inc., and others.
Where is Oric Pharmaceuticals, Inc. headquartered?: Oric Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 102 people. It has been publicly traded since 2020.